1. Ron Beasley, PharmD Candidate Preceptor: Soheyla Mahdavian, PharmD
CUtLASS TRIAL
Ron Beasley, PharmD Candidate
Preceptor: Soheyla Mahdavian, PharmD

2. CUtLASS TRIAL
Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study
Tested at Fourteen community psychiatric services in the English National Health Service.
Published in Archives of General Psychiatry in 2006

3. Objectives
To test the hypothesis that in people with schizophrenia SGAs improve quality of life across 1 year compared with FGAs.
Multisite, randomized controlled trial of antipsychotic drug classes, with
Blind assessments at 12, 26, and 56 weeks using intention-to-treat analysis.

4. Methods
227 people aged 18 to 65 years with DSM-IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects.
Following randomization, the referring psychiatrists would choose a medication from the assigned class to administer for up to 1 year's duration.

5. Methods Cont. The FGAs were *Not in the USA
Chlorpromazine hydrochloride,
Flupenthixol *
Haloperidol
Loxapine
Methotrimeprazine*
Sulpiride*
Trifluoperazine hydrochloride
Zuclopenthixol*
Depot Preperations
Fluphenazine decanoate,
Flupentixol decanoate *
Haloperidol decanoate
Pipothiazine palmitate *
Zuclopenthixol decanoate *
*Not in the USA

6. Methods Cont. SGAs were Risperidone Olanzapine Amisulpride* Zotepine*
Quetiapine
*Not in the USA

7. Criteria Inclusion Exclusion
DSM-IV schizophrenia, schizoaffective disorder, or delusional disorder
Age 18 to 65 years
At least 1 month since the first onset of positive psychotic symptoms
Psychiatrist electing to change the current FGA or SGA treatment because of inadequate clinical response or in- tolerance.
Substance misuse or a medical disorder considered clinically to be the major cause of positive psychotic symptoms and a history of neuroleptic malignant syndrome.

8. Outcome Measurements
The primary outcome measure was total score on the Quality of Life Scale (QLS), assessed blindly at baseline and at Weeks 12, 26, and 52 of the study.
Secondary outcome measures included:
Positive and Negative Syndrome Scale (PANSS)
Calgary Depression Scale
Various scales looking at adverse medication effects
Participant satisfaction

9. Results
SGAs did not show superiority in improvement in the QLS. In fact, there was a numerical trend toward greater improvement with the FGA cohort.
Healthcare costs were similar in both groups with psychiatric inpatient hospitalization responsible for the majority of the expense.
Although SGAs were more expensive than FGAs, total antipsychotic medication cost was a relatively small proportion of total expenses (2.1% and 3.8% for FGAs and SGAs, respectively).

10. Results cont.
There was no measurable difference between the 2 cohorts in:
Positive or negative symptoms
Depressive symptoms
Adverse effects

11. Critique (Pros)
It is consistent with several other recent studies showing minimal to no clinical or cost-savings advantage of SGAs over FGAs
It is a practical, blinded, well-designed trial that contains discussion about why the original premise (SGA superior to FGA) could not be proven
Effect size, sample size, statistical power, utility of the QLS all were assed for bias

12. Critique (Cons) This study fails to answer key questions:
Are second-generation antipsychotic medications overrated?
Do SGA’s really provide patients with an advantage over first-generation antipsychotics?
Limited sample size and statistical power
Psychiatrists may have been less ready to change from SGAs compared with FGAs in treating the patients skewing results.

13. References
1. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Awad A. Comparative evalu- ation of conventional and novel antipsychotic drugs with reference to their sub- jective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:
2. National Collaborating Centre for Mental Health. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London, En- gland: National Institute for Clinical Excellence; 2002.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second- generation antipsychotics. Arch Gen Psychiatry. 2003;60: